Study on the Diagnostic Value of Serum Pepsinogen and Gastrin-17 in Gastric Cancer and Atrophic Gastritis

An Yunfei,Ding Fei,Cai Bei,Zhao Wenling,Hu Jing,Huang Zhuochun,Li Lixin
DOI: https://doi.org/10.3877/cma.j.issn.2095-5820.2019.04.006
2019-01-01
Abstract:Objective To investigate the level changes and clinical value of serum pepsinogen (PG) and gastrin-17 (Gastrin-17) in non-atrophic gastritis, atrophic gastritis and gastric cancer. Method Pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), gastrin-17 (G-17) and the PGⅠ/PGⅡ (PGR) levels were measured in 37 patients with non-atrophic gastritis, 37 patients with atrophic gastritis and 65 patients with gastric cancer by enzyme-linked immunosorbent assay. Results The PGⅠand PGR in the atrophic gastritis group were significantly lower than those in the non-atrophic gastritis group (P<0.05). The PGⅠand PGR levels in the gastric cancer group were significantly lower than those in non-atrophic gastritis group and atrophic gastritis group (P<0.05). The level of PGⅡ in the gastric cancer group was significantly higher than that in the non-atrophic gastritis group (P<0.05). The G-17 in the gastric cancer group was significantly higher than that that in the atrophic gastritis and non-atrophic gastritis group (P<0.05). The G-17 in the gastric antrum cancer group was significantly higher than that in the gastric body cancer group (P<0.05). Conclusions Pepsinogen and gastrin can be used as serological markers for screening atrophic gastritis and gastric cancer. Serum gastrin-17 has great clinical value in distinguishing gastric antrum and gastric body cancer. Key words: Pepsinogen; Stomach neoplasms; Atrophic gastritis; Gastrin-17
What problem does this paper attempt to address?